SYNTHETIC SITE-SPECIFIC RNA EDITING ENTITIES
The present disclosure provides compositions comprising synthetic site-specific RNA editing entities engineered to target pathogenic RNA comprising a CAG repeat associated with a CAG repeat disorder. Also disclosed herein are methods of treating the CAG repeat disorders of the present disclosure, such as Huntington's disease with the compositions and pharmaceutical formulations comprising the compositions disclosed herein.
1 .- 100 . (canceled)
101 . A synthetic RNA binding domain comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NO: 6.
102 . A polynucleotide sequence encoding the synthetic RNA binding domain of claim 101 .
103 . A vector comprising the polynucleotide sequence of claim 102 .
104 . The vector of claim 103 , wherein the vector is a viral vector.
105 . A pharmaceutical composition comprising the vector of claim 103 and a pharmaceutically acceptable excipient, carrier, or diluent.
106 . A synthetic RNA binding domain comprising an amino acid sequence with at least 95% sequence identity to SEQ ID NO: 10.
107 . A kit comprising the synthetic RNA binding domain of the claim 106 .
108 . A polynucleotide sequence encoding the synthetic RNA binding domain of claim 106 .
109 . A cell or cell culture expressing the polynucleotide sequence of claim 108 .
110 . A vector comprising the polynucleotide sequence of claim 108 .
111 . A method of delivering a synthetic site-specific RNA editing entity to a cell, comprising administering to the cell the vector of claim 110 .
112 . The method of claim 111 , wherein the polynucleotide sequence is integrated into the genome of the cell.
113 . A synthetic site-specific RNA editing entity targeting a pathogenic RNA that comprises a CAG repeat, the synthetic site-specific RNA editing entity comprising: (i) a synthetic RNA binding domain; and (ii) a cleavage domain; wherein the synthetic RNA binding domain comprises an amino acid sequence comprising (Cys/Ser/Asn)XxxXxxXxxGln that binds to adenine, wherein Xxx is any amino acid.
114 . A method of treating a subject in need thereof, comprising administering to the subject the synthetic site-specific RNA editing entity of claim 113 .
115 . The method of claim 114 , wherein the subject has a CAG repeat-associated disorder.
116 . The method of claim 114 , wherein the subject has Huntington's disease (HD), spinocerebellar ataxia (SCA), dentatorubral-pallidoluysian atrophy (DRPLA), or spinal and bulbar muscular atrophy (SBMA).
117 . The method of claim 116 , wherein the subject has the HD.
118 . The method of claim 116 , wherein the subject has the SCA.
119 . The method of claim 118 , wherein the subject has spinocerebellar ataxia (SCA) type 1, SCA type 2, SCA type 3, SCA type 6, SCA type 7, or SCA type 17.
120 . The method of claim 119 , wherein the subject has the SCA type 3.